Currently, screening for BCR-ABL mutations is not recommended in newly diagnosed CP-CML patients [24] because the frequency of mutations in these patients was found to be low in previous studies, these mutations may not necessarily correlate with response, and the screening costs are prohibitive [18], [24], [36], [39]–[40]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.